Aviva Bio’s AVA-291 Emerges as Best-in-Class Therapy to Address FDA-Identified Safety Concerns of Testosterone for Women

[#item_full_content]CONCORD, Mass.–(BUSINESS WIRE)–Aviva Bio, a biotechnology company developing next-generation hormone therapies, highlighted the importance of advancing testosterone therapies designed for women following the FDA’s September 17 public workshop, “Testosterone Use in Menopausal Women.” The workshop brought together federal health officials, external experts, clinicians, and patient advocates to examine the scientific evidence, regulatory considerations, and critical knowledge gaps surrounding te